AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. Co.'s full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. Rather than advancing its own clinical pipeline of drug candidates, Co. forges partnerships with drug developers of all sizes, from pharmaceutical to small biotechnology companies. In a collaboration with Eli Lilly and Company, Co. has applied its technology stack to co-develop LY-CoV555, a potential antibody therapy to treat and prevent COVID-19.